Pharma — India Patent Cases
1,090 decisions indexed
Page 35 of 37 · 1,090 total
M/S UCB FARCHIM SA v.M/S Cipla Ltd.
The petitions challenged orders passed by the Assistant Controller of Patents rejecting patent applications or related documents. The court examined the statutory scheme of the Patents Act, particularly concerning pre-grant and post-grant opposition procedures introduced by the 2005 Amendment Act.
Glaxo Group Ltd. v.Union Of India & Ors.
Glaxo Group Ltd. challenged the Intellectual Property Appellate Board's (IPAB) dismissal of its trademark registration appeal for 'VOLMAX.' The Delhi High Court intervened, finding that the IPAB had failed to properly consider key legal issues regarding deceptive similarity and the concept of a family of trademarks. Consequently, the High Court set aside the IPAB's order, restoring Glaxo's appeal to be decided afresh on all merits.
Modi Mundi Pharma Pvt. Ltd. v.Matrix Formulations & Anr.
The Delhi High Court ruled in favor of Modi Mundi Pharma Pvt. Ltd., finding that the defendant's use of 'NEUROCONTIN-800' infringed upon the plaintiff's registered trademark 'CONTIN'. The court held that the resemblance between the marks was likely to cause confusion and deceive consumers, thereby amounting to passing off. Consequently, the suit was decreed, granting permanent injunctions against the defendants and ordering them to surrender all infringing materials.
Glochem Industries Ltd. v.Cadila Healthcare Ltd.
Glochem Industries Ltd. challenged an order passed by the Assistant Controller of Patents & Designs that dismissed its representation by way of opposition against Cadila Healthcare Ltd.'s patent application for Clopidogrel Besylate. The Petitioners argued that the invention lacked enhancement in therapeutic efficacy, which was a core ground for opposition under the Patents Act. The Bombay High Court set aside the dismissal order and directed the matter to be reconsidered afresh by the Patent Office.
Dabur India Ltd. v.Sh. Ashok Aushadhi Udyog
Dabur India Ltd. filed a suit against Sh. Ashok Aushadhi Udyog alleging that the latter had adopted deceptively similar labels for ayurvedic tonics, specifically Dashmularishta and Ashokarishta. Dabur claimed ownership of copyright in the artistic work comprising these distinctive product labels. The court found sufficient evidence to establish Dabur's proprietary rights and ruled that the defendant's use constituted infringement. Consequently, the suit was decreed with permanent injunctions and punitive damages awarded.
Vittal Mallya Scientific Research Foundation v.Indfrag Limited
The applicants filed three applications seeking supplementary instructions to IIT, Madras, to examine whether the respondent's production process for Double Metal Salt of HCA infringed upon the applicants' patents. The court dismissed these applications, holding that they constituted an abuse of the process and were unnecessary since the trial was yet to commence.
Bayer Corporation v.Union of India
Bayer Corporation, holding a patent for the drug Sorafenib tosylate, challenged the licensing process of its competitor, Cipla, arguing that Cipla's application for 'Soranib' constituted an infringement. Bayer contended that granting the license would violate Section 48 of the Patents Act and contravene the definition of a 'spurious drug' under the Drugs and Cosmetics Act. The Delhi High Court ultimately dismissed the writ petition, holding that unpatented drugs cannot be deemed 'spurious drugs,' thereby upholding the procedural integrity of the licensing process.
The Petitioner/Appellant (Name not specified) v.Cadilla Pharmaceuticals Ltd
The Madras High Court dismissed a petition seeking an interim injunction against Cadilla Pharmaceuticals Ltd, which was accused of infringing the petitioner's registered trademark CEFI-XL with its mark CEFOLAC-XL. The court found that there was no prima facie case of deception or confusing similarity between the two marks. Furthermore, the court noted the petitioner's delay in bringing the action (laches) and concluded that the balance of convenience favored the respondent, thus denying the temporary injunction.
Aventis Pharmaceuticals Inc. and AMR Technology, Inc. v.Barr Laboratories, Inc., Ranbaxy Laboratories Ltd. and Ranbaxy Pharmaceuticals Inc.
Aventis Pharmaceuticals Inc. and AMR Technology, Inc. filed a petition seeking permission from the Punjab-Haryana High Court to execute a letter of request issued by the United States District Court for the District of New Jersey under the Hague Convention. The request sought evidence and documents related to patent infringement concerning Aventis's ALLEGRA® drug products manufactured using intermediates supplied by Ind-Swift Laboratories Ltd.
F. Hoffmann-La Roche Ltd. v.Cipla Ltd.
F. Hoffmann-La Roche Ltd. (Roche) appealed a decision that denied an interim injunction against Cipla Ltd. regarding the manufacturing and sale of the generic drug Erlocip, which is based on the patented molecule Erlotinib (Tarceva). The plaintiffs claimed patent rights over this cancer treatment. However, the Delhi High Court dismissed the appeal, finding that the defendant had raised credible challenges to both the validity of the patent and the prima facie case for infringement. Crucially, the court emphasized that public interest in greater access to life-saving drugs must outweigh the interest in granting an injunction.
Vee Excel Drugs & Pharmaceuticals Ltd. v.Hab Pharmaceuticals & Research Lim.
Vee Excel Drugs & Pharmaceuticals Ltd. filed a suit seeking permanent injunction against Hab Pharmaceuticals & Research Lim., alleging infringement of its registered trademark 'Vega Asia' and associated copyrights in packaging designs. The defendant countered by asserting prior use, holding its own registrations (including the mark 'Vegah'), and crucially, arguing that the plaintiff had suppressed material facts regarding pending rectification applications and previous complaints. The Delhi High Court ultimately dismissed the plaintiff's interim injunction application, finding that the plaintiff's conduct disentitled them from relief at this stage.
M/S Bal Pharma Ltd. v.M/S Glenmark Pharmaceutical Ltd.
The Madras High Court dismissed a civil revision petition filed by M/S Bal Pharma Ltd against an order passed by the Intellectual Property Appellate Board (IPAB). The IPAB had granted a stay on the registration of a trade mark application, which was sought by Glenmark Pharmaceutical Ltd. The High Court found the IPAB's decision to be balanced and reasonable, noting that allowing immediate registration would create significant complications for the parties involved. Consequently, the court directed the IPAB to expedite the hearing and final disposal of the original appeal.
Indian Network for People living with HIV/AIDS v.Union of India
The petitioners, representing people living with HIV/AIDS, challenged the grant of Patent No.207232 by F.Hoffmann-La Roche AG for Valganciclovir derivative. They argued that since India adopted a product patent regime in 2005, any product invention disclosed prior to 1995 should be considered public domain and lack novelty. The court allowed the writ petition, setting aside the patent grant.
Sun Pharmaceuticals Industries Limited v.Cipla Limited
The Delhi High Court granted an interim injunction favoring Sun Pharmaceuticals against Cipla regarding the use of the trademark THEOBID-D. Despite arguments from the defendant citing statutory requirements for registered assignment, the court found that the plaintiff was entitled to protection based on prima facie rights and the potential irreparable injury caused by continued infringement in the pharmaceutical sector. The order restrained the defendant's associates from using the disputed mark during the pendency of the suit.
Natco Pharma Limited v.Union Of India & Ors.
The Supreme Court addressed an appeal concerning patentability issues involving crystal modification of an N-Phenyl-2-Pyrimidineamine derivative. The core issue was the absence of a qualified Technical Member in the Intellectual Property Appellant Board (IPAB).
Glaxo Smith Kline Plc v.Controller Of Patents & Designs
The dispute concerned the application for Exclusive Marketing Right (EMR) under the Patents Act. After the relevant chapter was repealed by amendment in 2005, the appellants challenged the High Court's decision which had allowed appeals based on the argument that no further consideration of EMR was possible post-amendment. The Supreme Court ruled that due to Section 6 of the General Clauses Act, the vested right to challenge earlier orders remained alive.
Macleods Pharmaceuticals Ltd. v.Alembic Limited
Macleods Pharmaceuticals Ltd. challenged an ex-parte injunction passed by the lower court against it, which restrained the use of its trade mark GEMIMAC due to alleged similarity with Alembic Limited's reputed trade mark GERIMAC. The appellant argued that the injunction was granted without issuing prior notice or recording adequate reasons, violating procedural requirements under the Code of Civil Procedure. The Gujarat High Court admitted the appeal and intervened, restricting the scope of the injunction until a proper hearing could take place.
Troikaa Pharmaceuticals Ltd. v.Pro Laboratories (P) Ltd. And Anr.
Troikaa Pharmaceuticals Ltd. filed a civil suit seeking permanent injunction against Pro Laboratories (P) Ltd. for infringing its registered design of a D Shape Tablet. The plaintiff claimed that the defendant was manufacturing and marketing tablets with identical shape and configuration, thereby exploiting the unique aesthetic innovation protected under the Designs Act, 2000. After considering the prima facie case, balance of convenience, and irreparable injury, the court granted temporary injunctions to protect the registered design.
F. Hoffmann-La Roche Ltd. v.Cipla Limited
This case involves F. Hoffmann-La Roche Ltd. seeking an ad-interim injunction against Cipla Limited for allegedly infringing its patent on the cancer drug Erlotinib (marketed as Tarceva). The court examined the balance between protecting the innovator's intellectual property rights and ensuring public access to a life-saving generic medication. Ultimately, the court dismissed the request for an immediate injunction, prioritizing the public interest in patient access.
Paras Pharmaceuticals Ltd. v.Ranbaxy Laboratories Ltd.
Paras Pharmaceuticals Ltd. filed a suit against Ranbaxy Laboratories Ltd., alleging that Ranbaxy was using negative advertisement and TV commercials for its pain reliever VOLINI to disparage Paras's popular product, MOOV. The court found that Ranbaxy's commercial depicted a box identical in artistic work and color scheme to MOOV, subtly suggesting that MOOV was inferior. Consequently, the Gujarat High Court allowed the appeal and directed Ranbaxy to change its packaging colors and cease using the appellant's artwork.
Reddy Pharmaceuticals Ltd. v.Dr. Reddy'S Laboratories Ltd.
The Delhi High Court dismissed an appeal, upholding the injunction granted against Dr. Reddy's Laboratories Ltd. The case centered on whether the defendant was passing off its products by using a deceptively similar name and logo ('Reddy') that accrued goodwill to the plaintiff's established trademark 'Dr. Reddy'. The court affirmed that while the defendant had initially been an agent, its subsequent entry into manufacturing finished dosage forms under the disputed brand constituted infringement. The judgment emphasized that even if alternative views were possible on the facts, appellate courts should not interfere with a trial court's properly exercised discretion. This ruling reinforces the importance of protecting established trade names and goodwill in the pharmaceutical sector.
Ranbaxy Laboratories Ltd. v.Pe-Mm Sp. Zo.O And Anr.
The Delhi High Court ruled in favor of Ranbaxy Laboratories Ltd. in its suit against Pe-Mm Sp. Zo.O regarding trademark infringement via domain name squatting. The court found that the defendant's registration of 'www.ranbaxy.eu' was unauthorized and deceptively similar to Ranbaxy's registered global trademark, 'RANBAXY'. Citing established principles, the judgment affirmed that a proprietor has a legitimate interest in protecting its brand identity across digital domains.
Novartis AG v.Union of India
Novartis AG challenged the constitutional validity and TRIPS compliance of Section 3(d) of the Patents Act, 1970 (as amended in 2005), arguing it was vague and arbitrary. The petitioner sought a declaration that the section was unconstitutional and requested permission to allow a specific patent application.
Fdc Limited (and others) v.Sanjeev Khandelwal Prem Niwas (and others)
This Civil Revision Petition challenged the grant of an ex parte ad-interim injunction by the trial court against several pharmaceutical companies. The petitioners argued that the injunction was arbitrary, as they were based outside the jurisdiction and no substantive evidence of infringement had been considered. The Madras High Court suspended the interim order, emphasizing that such a drastic relief requires elaborate oral and documentary evidence from both sides before judicial scrutiny.
Ayurherbs Pharmaceuticals Private Limited v.Three-N-Products Private Limited
The Delhi High Court ruled in favor of Ayurherbs Pharmaceuticals, finding that Three-N-Products Private Limited was engaging in passing off by using the name 'Ayur' in its corporate identity. Despite arguments regarding product differences and derivation from Ayurveda, the court held that the use of the suffix 'Ayur Herbs Pharmaceuticals Private Limited' was likely to confuse the ordinary purchaser. This judgment reinforces the principle that trademark infringement can occur even if the goods are not identical, provided there is a likelihood of deception.
Bilcare Limited v.The Supreme Industries Ltd.
Bilcare Limited filed suits against The Supreme Industries Ltd. alleging infringement of its patented metallized PVC film used in pharmaceutical packaging. Bilcare sought a temporary injunction to restrain the respondents from manufacturing or selling the infringing product. However, the Delhi High Court dismissed the appeals filed by Bilcare, upholding the trial court's decision. The court found that the essential conditions for granting an injunction—prima facie case, balance of convenience, and irreparable loss—leaned in favor of the respondents.
Bilcare Limited v.M/s.Associated Capsules Private Limited
Bilcare Limited filed a suit seeking permanent injunction against M/s.Associated Capsules Private Limited for infringing its registered patent (No. 197823) related to 'metallized' film used in pharmaceutical packaging. The court examined the validity and infringement claims, ultimately finding that the plaintiff failed to establish a prima facie case.
Sun Pharmaceutical Industries Limited v.Cipla Limited
The Bombay High Court rejected Sun Pharmaceutical Industries Limited's application for an interim injunction against Cipla Limited regarding the use of the trade mark 'Graniset'. Despite the similarity in marks and their use in treating nausea related to chemotherapy, the court found that the plaintiff lacked a prima facie proprietary right in the mark. The judgment highlighted the importance of prior user rights versus registration, while also noting the plaintiff's failure to provide supporting medical evidence for potential consumer confusion.
Novartis Ag. v.Cipla Ltd.
Cipla Ltd. opposed Novartis AG's patent application for a new crystal form of imatinib mesylate. The IPAB found that the subject matter was merely a new form of a known substance without significant enhancement in efficacy, thus failing Section 3(d). Furthermore, the court disqualified the application due to improper claiming of Swiss priority.
German Remedies Ltd. v.Commissioner Of Central Excise
German Remedies Ltd. challenged the Commissioner's decision regarding the classification and duty rate for its Acetyl Salicylic Acid (ASA) tablets. The dispute centered on whether the product, which was previously classified as a patent/proprietary medicament due to branding, should be treated as a generic product after dropping the trade mark. The Tribunal found that 'ASA' is merely an abbreviation of the chemical name and not a proprietary designation.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.